Short answer
Beta Bionics, Inc. (BBNX) filed its Q3 2026 10-Q quarterly report on Oct 27, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $36M (up 30.3% year over year) with net income of −$24M.
Q3 2026 key financials · XBRL
- Revenue
- $36M
- +30.3% YoY · +10.9% QoQ
- Net income
- −$24M
- −71.4% YoY · −4.1% QoQ
- Operating margin
- -74.9%
- Gross margin
- 57.3%
- EPS (diluted)
- −$0.52
- −79.3% YoY · +1.9% QoQ
Source: XBRL data from the Beta Bionics, Inc. (BBNX) Q3 2026 10-Q on SEC EDGAR. USD.
Beta Bionics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $35.5M, up from $27.3M YoY, driven by higher single-use product volumes and new patient starts
- Gross margin 57.3% vs 55.5% YoY, while net loss widened to $24.4M from $14.2M
- Single-use products strongest line, 68% of sales vs 47%; PBP sales 38% vs 23% YoY
- Cash, equivalents and investments $373.6M; operating cash used $50.7M, follow-on offering provided $161.8M
- Mint launch targeted Q1 2027; FDA Warning Letter remediation, inflation, tariffs and supply risks remain headwinds
Risk Factors
- Mint FDA clearance in September 2026 created commercialization risk, with U.S. launch targeted by end of first quarter 2027
- 3D Intelligence 510(k) withdrawal in October 2026 delayed next-generation iLet 3D and Mint 3D plans
- FDA Warning Letter cited Quality Management System, Medical Device Reporting, and Correction and Removals deficiencies
- September 2026 securities class action alleges federal securities-law violations concerning iLet safety, efficacy, and commercial success
- September 2026 follow-on offering raised net proceeds of approximately $161.3 million, but additional capital may still be required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Beta Bionics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.